

25th March 2015

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxembourg

Dear Sirs,

We are forwarding herewith copy of press release dated 25th March 2015 titled as "Cipla announces the launch of generic drug Sofosbuvir in India under the brand name 'Hepcvir'".

Kindly note that this development is in the ordinary course of business and is being sent to stock exchanges out of abundant caution.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary

Encl.: as above



Press Release

Cipla announces the launch of generic drug Sofosbuvir in India under the brand name 'Hepcvir'

India, Mumbai, March 25th, 2015: Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announces the launch of generic drug Sofosbuvir in India under the brand name 'Hepcvir'. Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week's time.

Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for hepatitis C treatment and represents a paradigm shift in the existing hepatitis C management. The high potency, high barrier to resistance, pangenotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of sofosbuvir makes it a breakthrough drug in hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90%.¹

Globally, it is estimated that 170-185 million people (about 3% of the world's population) are chronically infected with hepatitis C virus (HCV). Untreated chronic hepatitis C increases the risk of cirrhosis of liver, liver failure and hepatocellular carcinoma.² In India alone, it is estimated that 12-18 million patients are infected with Hepatitis C which is several fold greater than those with HIV/AIDS. Globally, HCV is implicated in 28% of cases of liver cirrhosis and 26% of cases of hepatocellular carcinoma, which accounts for almost 500,000 deaths per year.³

Commenting on the launch of Hepcvir, **Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited** said, "Cipla has always brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B and is a leader in India with anti-virals; hence, Cipla has made it a priority to bring Hepcvir to patients in India as well as the other developing nations."

Dr Jaideep Gogtay, Chief Medical Officer, Cipla said: "The benefits of Hepcvir will be felt by patients who will have much lower discomfort while on the treatment and therefore much higher levels of adherence. Sofusbuvir marks a new era of medicines in oral treatment of Hepatitis C which reduce the need for injectibles. It is hoped that in the future these drugs will eventually mean a totally oral regimen."

The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries.

About Cipla Limited

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150

countries. Cipla's portfolio includes over 1500 products in various therapeutic categories with one quality standard globally. Cipla's turnover in 2013/14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Media Contacts:

Corporate Communications

Charlotte Chunawala

Mobile: +91 7506257377

E Mail: charlotte.chunawala@cipla.com;

Jaisingh Balakrishnan

Mobile: +91 9833836185

E Mail: jaisingh.krishnan@cipla.com;

REFERENCES

1. Bourlière M, Oules V, Ansaldi C, et al. Sofosbuvir as backbone of interferon free treatments. Dig Liver Dis. 2014 ;46 Suppl 5:S212-20.
2. Chung RT, Baumert TF. Curing chronic hepatitis C—the arc of a medical triumph. N Engl J Med. 2014;370:1576–1578.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.